Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtlantic Lithium Regulatory News (ALL)

Share Price Information for Atlantic Lithium (ALL)

Share Price is delayed by 15 minutes
Get Live Data
16.45    -0.20 (-1.20%)
Bid:
16.45
Ask:
16.70
Spread: 0.25 (1.52%)
Market Cap: £131.85m
ALL Live PriceLast checked at - London Stock Exchange

Intraday Atlantic Lithium Share Chart

Trading Update

24 Jun 2013 07:00

RNS Number : 6463H
Allocate Software PLC
24 June 2013
 



24 June 2013

 

ALLOCATE SOFTWARE PLC

("Allocate" or "the Company")

 

Full Year Trading Update

 

Allocate Software (AIM: ALL), the leading provider of workforce and compliance optimisation solutions, announces an update on trading for its financial year ended 31 May 2013. The Company's audited results will be announced in the week commencing 22 July 2013.

 

Overview

 

Allocate delivered a very strong second half performance with full year results in line with market expectations for both revenue and EBITA. The Company's cash performance has materially exceeded analysts' expectations due to the continuing transition in the Company's business model to one based more on recurring revenues and due to improvements in working capital.

 

Business

 

The Healthcare business achieved another successful year securing a significant number of agreements for both new products and new customers.

 

UK Healthcare bookings are ahead of revenue because the number of recurring orders secured has been higher than anticipated. The financial effect of this is that cash, deferred revenue and contracted, unbilled orders in hand are higher than anticipated. As a result, this will increase the visibility and predictability of future years' revenue streams.

 

The number of new HealthRoster customers secured by the Company was slightly fewer than the previous financial year but met management's expectations for the second half of the current year. Several of the new customers secured were competitor displacements and HealthRoster renewals continued at the previously recorded 100% renewal rate.

 

The Allocate Cloud, launched in July, has exceeded management original plans with new customers entering agreements in addition to existing customers who have already licensed the software, committing to the Cloud service. A further positive impact of this performance is on cash flow, as noted above.

 

Sales of the Medics products enjoyed a good year with a number of new customers signing contracts and a high renewal rate of annual subscriptions. Multiyear renewals have been secured with substantially more customers than anticipated demonstrating high levels of customer satisfaction. A further beneficial impact of the multiyear renewals is on cash flow, as noted above.

 

The migration from HealthRoster V9 to V10 continues in line with management plans. Customers that have migrated are located primarily in the UK, along with customers in the USA and Australia.

 

The Defence business had a productive year securing a major contract with Royal Australian Airforce as well as securing a series of important professional services contract extensions.

 

The Maritime business had a successful year securing a new offshore services customer in addition to closing a number of important follow on licence and services contract extensions.

 

Ian Bowles, Chief Executive Officer of Allocate commented: "2012 was a very important year for Allocate. We launched HealthRoster V10, our most important product for many years and we launched the Allocate Cloud, a completely new HealthRoster service that has been extremely well received by our customers and prospects. Sales of our Medics portfolio of applications exceeded management plans and we continued to secure our 100% renewal rate on HealthRoster. Both the Defence and Maritime businesses again performed solidly.

 

"At the same time as delivering revenue in line with expectations we continued our transition to a business with higher recurring and deferred revenues. Although revenue growth has been masked by both a large order in the prior year and the move to higher recurring and deferred revenues, billings and cash show more significant growth and more fairly reflect the true underlying progress that Allocate has achieved this year.

 

"We remain well placed to support the broader healthcare market in general and specifically the NHS in its goals of improving patient care whilst driving improvements in efficiency."

 

Enquiries:

 

Allocate Software plc

Ian Bowles - Chief Executive Officer

Chris Gale - Chief Financial Officer

Martin Jeffries - Marketing Director

 

Tel: +44 (0) 20 7355 5555

Numis Securities

Nominated adviser - Michael Meade / Simon Willis/ Richard Thomas

Corporate Broking - James Black

 

Tel: +44 (0) 20 7260 1000

Gable Communications

Justine James / John Bick

 

Tel: +44 (0) 20 7193 7463

M: +44 (0) 7525 324431

 

About Allocate Software plc

Allocate Software plc is the leading workforce optimisation software applications provider for world-wide organisations with large, multi-skilled workforces. With a blue chip client base spanning the public and private sector, its key vertical markets include: Healthcare and Defence.

 

At the core of the business is Allocate's workforce optimisation software, which organisations use to deploy the right people with the right skills, to the right place at the right time. Headquartered in London, Allocate provides services and support to its increasing international customer base through regional offices in the UK, Sweden, USA, Australia and Malaysia.

 

Allocate is quoted on the London Stock Exchange (AIM: ALL). For further information please visit www.allocatesoftware.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUAVBRONANUAR
Date   Source Headline
20th Nov 20247:00 amRNS-RInvestor Presentation - Swiss Mining Institute
5th Nov 20247:00 amRNSTR-1 Notification of Major Holdings
30th Oct 20247:00 amRNSNotice of AGM
25th Oct 20247:00 amRNSSuccessful Completion of A$10m Equity Placing
24th Oct 20244:35 pmRNSA$9 million Equity Placing
24th Oct 20244:31 pmRNSQuarterly Activities and Cash Flow Report
8th Oct 20247:00 amRNSGrant of Mine Operating Permit
18th Sep 20247:00 amRNS2024 Annual Financial Report
12th Sep 20247:00 amRNSGrant of Ewoyaa Lithium Mining Project EPA Permit
16th Aug 20247:00 amRNSGrant of Performance Rights to Employees
30th Jul 20247:15 amRNSQuarterly Activities and Cash Flow Report
30th Jul 20247:00 amRNSNew Dog-Leg Target Delivers Increase to Ewoyaa MRE
12th Jul 20248:30 amRNSEwoyaa Lithium Project Update
10th Jul 20247:00 amRNSFatal Incident at the Ewoyaa Lithium Project
30th May 20247:00 amRNSField Work Underway at Senya Beraku Licence
15th May 20249:55 amRNSBoard Appointment - Replacement
15th May 20247:00 amRNSBoard Appointment
10th May 20247:00 amRNSAdmission to Trading on the Ghana Stock Exchange
7th May 20247:10 amRNSConference Attendance – CG Global Metals & Mining
7th May 20247:00 amRNSDog-Leg Delivers Further High-grade Intersections
2nd May 20247:00 amRNSApproval to List on the Ghana Stock Exchange
24th Apr 20247:00 amRNSQuarterly Activities and Cash Flow Report
18th Apr 20247:00 amRNSExploration-focused Investor Webinar
16th Apr 20247:00 amRNSInvestor Presentation - Paydirt Battery Minerals
8th Apr 20247:00 amRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSFurther Broad and High-Grade Drill Intersections
15th Mar 20247:00 amRNSHalf-year Financial Report
27th Feb 20247:00 amRNSConference Attendance
15th Feb 20247:00 amRNSDirector/PDMR Dealings
5th Feb 20247:00 amRNSMultiple Broad and High-Grade Drill Intersections
2nd Feb 20247:00 amRNSConference Attendance – Mining Indaba
1st Feb 20248:20 amRNSInvestor Presentation - Investor Webinar
31st Jan 20247:00 amRNSQuarterly Activities and Cash Flow Report
29th Jan 20247:00 amRNSInvestor Webinar
25th Jan 20247:00 amRNSUpdate on Competitive Offtake Partnering Process
24th Jan 20247:00 amRNSCompletion of US$5m MIIF Subscription
23rd Jan 20247:00 amRNSTR-1 Notification of Major Holdings
2nd Jan 20247:00 amRNSCorporate Update - Director / PDMR Shareholding
29th Dec 20237:00 amRNSCorporate Update - Director / PDMR Shareholding
28th Dec 20237:00 amRNSGrant of PDMR Performance Rights
22nd Dec 20237:00 amRNSDirector / PDMR Dealings & Shareholding Update
21st Dec 20237:00 amRNSCorporate Update - Director / PDMR Dealings
20th Dec 20237:00 amRNSBoard Changes
15th Dec 20237:00 amRNSSuccessful Completion of A$8million Equity Placing
14th Dec 20234:45 pmRNSA$7 million Equity Placing
12th Dec 20237:00 amRNSMaiden Feldspar Mineral Resource Estimate
30th Nov 202311:57 amRNSAmended Constitution
30th Nov 202311:50 amRNSResult of Annual General Meeting
30th Nov 20237:02 amRNSAGM Statement
28th Nov 20237:00 amRNS106m Continuous Pegmatite Interval Reported

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.